begin
centuri
antimicrobi
resist
common
develop
everi
class
antimicrobi
drug
appear
spread
new
clinic
nich
describ
determin
like
influenc
futur
epidemiolog
health
impact
antimicrobialresist
infect
understand
factor
ultim
optim
prevent
strategi
unpredict
futur
antibiot
therapi
indiscrimin
use
may
turn
medicin
flood
temporarili
clean
heal
ultim
destroy
life
felix
marti
ibanez
f
decad
problem
contain
antimicrobi
resist
preoccupi
polici
maker
member
academ
commun
preoccup
surpris
sinc
antimicrobi
resist
becom
public
health
concern
throughout
world
pessimist
viewpoint
low
chanc
success
stop
develop
antimicrobi
resist
repeatedli
report
fundament
predica
antimicrobi
drug
nonrenew
resourc
durat
benefit
avail
appear
limit
biolog
level
constraint
seen
therapi
diseas
condit
point
commentari
issu
emerg
infecti
diseas
emerg
antimicrobi
resist
unavoid
evolutionari
perspect
moreov
microorgan
unlik
fit
cost
antimicrobi
resist
reduc
spread
clinic
impact
sinc
subsequ
evolut
commonli
result
amelior
cost
paradigm
frame
microbiolog
perspect
could
summar
slogan
antibiot
therapi
use
lose
prompt
question
potenti
intervent
could
slow
dissemin
antimicrobi
resist
reduc
health
impact
next
decad
influenc
demand
use
antimicrobi
drug
near
futur
obstacl
toward
judici
use
decreas
transmiss
may
get
circumv
much
healthcar
regul
affect
antimicrobi
resist
abil
control
spread
short
need
complement
analysi
molecular
biolog
examin
determin
like
influenc
futur
epidemiolog
health
impact
antimicrobialresist
bacteri
infect
purpos
articl
space
reason
discuss
problem
viral
protozo
fungal
resist
controversi
use
antimicrobi
drug
anim
growth
promot
certain
analog
may
drawn
idea
present
factor
drive
uncertainti
regard
futur
dissemin
control
antimicrobi
resist
numer
divers
determin
group
categori
tabl
first
group
relat
molecular
characterist
pathogen
virul
transmiss
surviv
fit
issu
beyond
scope
articl
moreov
progress
microbiolog
detect
identif
infecti
pathogen
like
influenc
diagnost
uncertainti
prescrib
pattern
antimicrobi
drug
second
group
determin
link
prescrib
antimicrobi
drug
physician
may
chang
prescript
pattern
recent
data
differ
part
world
show
promis
area
third
group
relat
characterist
patient
popul
hostrel
factor
includ
infect
rate
casemix
characterist
also
consum
attitud
global
migrat
pattern
fourth
group
determin
link
macrolevel
factor
relat
healthcar
environ
factor
includ
regulatori
polici
may
influenc
use
antimicrobi
drug
infect
control
practic
technolog
develop
drug
discoveri
diagnost
uncertainti
key
driver
drug
misus
overus
lead
antimicrobi
select
pressur
increas
rate
resist
microb
risk
associ
untreat
microbi
infect
lack
accur
clinic
laboratori
predict
method
result
low
threshold
initi
empir
antimicrobi
drug
therapi
especi
infect
could
lifethreaten
futur
diagnosi
microbi
infect
may
improv
sever
level
allow
reduct
antimicrobi
select
pressur
first
new
diagnost
test
facilit
initi
withdraw
antimicrobi
therapi
soon
onset
symptom
especi
hospit
set
sever
new
biolog
marker
procalcitonin
solubl
trigger
receptor
express
myeloid
cell
propos
serv
either
goal
second
molecular
diagnost
may
increas
diagnost
accuraci
enabl
prudent
antimicrobi
drug
use
futur
amplif
technolog
dna
microarray
simplifi
autom
open
potenti
rapid
test
dunn
et
al
describ
scenario
year
sophist
laboratori
platform
realtim
amplifi
automat
obtain
analyz
clinic
sampl
abl
detect
potenti
pathogen
microb
within
minut
threat
bioterror
may
also
foster
research
rapid
molecular
diagnost
test
may
use
bedsid
third
new
diagnost
tool
may
avail
rapidli
distinguish
bacteri
viral
infect
ambulatori
set
fourth
profound
chang
seen
techniqu
use
perform
molecular
identif
antimicrobi
suscept
test
summari
sever
line
evid
suggest
number
molecular
immunolog
microbi
techniqu
chang
way
infecti
diseas
diagnos
reduc
diagnost
uncertainti
next
decad
clinician
immedi
risk
patient
outweigh
longterm
disadvantag
liber
use
antimicrobi
drug
one
promis
mean
reduc
antimicrobi
select
pressur
without
impair
patient
safeti
cessat
antimicrobi
drug
therapi
patient
bacteri
infect
great
progress
made
within
last
year
shorten
durat
treatment
antimicrobi
agent
predict
rule
design
earli
discontinu
antimicrobi
agent
valid
prospect
trial
optim
antimicrobi
drug
use
although
antimicrobi
drug
polici
guidelin
may
great
help
individu
decis
make
may
sensit
medic
commun
grow
problem
antimicrobi
drug
overus
resist
consequ
mani
industri
countri
either
number
antimicrobi
agent
prescript
volum
antimicrobi
use
decreas
last
year
especi
ambulatori
set
tabl
plateau
worldwid
antimicrobi
consumpt
seem
reach
lead
satur
market
state
recent
repres
pharmaceut
industri
awar
relationship
use
emerg
resist
led
effort
decreas
even
restrict
antibiot
use
therefor
decreas
posit
influenc
resist
market
decreas
market
potenti
bial
drug
use
resist
futur
increas
immunocompromis
patient
grow
lifeexpect
suscept
older
person
infect
could
indirectli
contribut
greater
antimicrobi
drug
use
dissemin
resist
microb
moreov
infecti
diseas
influenc
develop
area
patient
care
new
technolog
treatment
creat
new
infecti
diseas
elimin
exist
one
instanc
cancer
chemotherapi
led
new
type
suscept
host
infecti
diseas
problem
indirectli
impel
dissemin
antimicrobi
resist
within
hospit
key
trend
clinic
care
biomed
discoveri
like
influenc
antimicrobi
resist
increas
use
medic
devic
gene
therapi
better
manag
chronic
diseas
diabet
cancer
develop
like
reduc
type
resist
problem
help
spawn
other
global
threat
next
influenza
pandem
may
also
affect
prescrib
antimicrobi
drug
revers
trend
decreas
antimicrobi
drug
consumpt
convers
climat
chang
may
lead
decreas
respiratori
tract
infect
antimicrobi
drug
use
winter
month
global
migrat
megac
led
new
possibl
crosstransmiss
antimicrobi
resist
recent
event
terrorist
attack
bali
war
iraq
tsunami
southeast
asia
led
transfer
patient
infect
panresist
gramneg
bacteria
acinetobact
spp
part
world
caus
outbreak
public
health
concern
within
next
decad
global
mix
increas
popul
densiti
decreas
travel
time
facilit
spread
varieti
antimicrobialresist
pathogen
fluoroquinoloneresist
pneumococci
enter
microb
sinc
antimicrobi
resist
influenc
intern
travel
global
resist
may
turn
affect
nation
respond
especi
surveil
system
improv
qualiti
intern
pressur
may
appli
induc
chang
countri
antimicrobi
agent
abus
infect
control
polici
lax
situat
antimicrobi
resist
might
becom
compar
exist
infecti
problem
mad
cow
diseas
econom
pressur
may
contribut
complianc
uniform
control
measur
nevertheless
approach
control
global
spread
resist
remain
difficult
implement
requir
intens
surveil
screen
effort
although
interplay
health
belief
demand
antimicrobi
drug
wide
recogn
systemat
studi
exist
futur
influenc
cultur
set
antimicrobi
drug
use
relat
resist
rate
social
constraint
cultur
view
infecti
condit
requir
antimicrobi
treatment
exert
strong
influenc
use
particularli
communityacquir
pathogen
sever
countri
recent
taken
bold
step
launch
nation
campaign
educ
physician
patient
antimicrobi
misus
threat
resist
figur
campaign
show
promis
chang
attitud
behavior
among
public
healthcar
profession
repeat
regularli
campaign
like
reduc
inappropri
patient
request
antimicrobi
agent
conjunct
physician
educ
model
may
reduc
inappropri
antimicrobi
prescript
practic
ultim
may
slow
dissemin
certain
antimicrobialresist
pathogen
instanc
sever
countri
franc
spain
use
great
amount
antimicrobi
agent
decreas
pneumococc
resist
rate
among
invas
isol
note
recent
coincid
decreas
antimicrobi
drug
use
nationwid
campaign
introduct
conjug
pneumococc
vaccin
nevertheless
uncertainti
persist
possibl
neg
outcom
countermeasur
taken
pharmaceut
industri
oppos
campaign
modern
vaccinolog
develop
new
vaccin
like
contribut
decreas
transmiss
impact
antimicrobialresist
bacteria
near
futur
antimicrobi
agent
vaccin
potenti
durabl
control
infecti
agent
block
abil
dissemin
within
popul
expect
illustr
exampl
new
pneumococc
conjug
vaccin
base
encourag
result
countri
high
preval
pneumococc
resist
israel
franc
spain
unit
state
vaccin
like
reduc
incid
invas
diseas
due
resist
pneumococci
progress
pneumococc
vaccin
develop
expect
conjug
vaccin
includ
serotyp
yet
uncertainti
remain
regard
serotyp
replac
emerg
resist
nonvaccin
serotyp
vaccin
prevent
invas
antimicrobialresist
infect
launch
within
next
year
potenti
candid
vaccin
multidrugresist
staphylococci
enterococci
clinic
studi
need
confirm
promis
preliminari
result
intens
select
pressur
antimicrobi
drug
use
import
factor
emerg
resist
inconsist
applic
infect
control
guidelin
hospit
personnel
larg
account
dissemin
resist
healthcar
set
infect
control
measur
limit
spread
antimicrobi
resist
increasingli
well
defin
despit
increas
preval
resist
sever
import
pathogen
success
control
clinic
impact
sever
countri
recent
report
stabil
decreas
infect
rate
due
multidrugresist
staphylococcu
aureu
next
year
see
increas
infect
control
research
intervent
improv
patient
safeti
hand
hygien
alcoholbas
hand
rub
shown
decreas
transmiss
resist
organ
campaign
sponsor
world
health
organ
promot
practic
throughout
world
earli
screen
isol
patient
carri
resist
organ
also
appear
decreas
spread
resist
microorgan
may
wide
implement
expert
suggest
multimod
approach
use
combin
differ
measur
exampl
aggress
infect
control
activ
surveil
cultur
hand
hygien
possibl
antimicrobi
control
effect
slow
even
halt
increas
trend
healthcareassoci
antimicrobi
resist
antimicrobi
use
affect
reimburs
polici
financi
incent
healthcar
regul
forecast
polit
regulatori
develop
area
present
major
challeng
alway
shortterm
lack
predict
regard
polit
decisionmak
unexpect
epidemiolog
situat
bioterrorist
attack
sever
acut
respiratori
syndrom
quickli
influenc
perceiv
medic
need
look
futur
impact
healthcar
regul
mani
believ
polit
measur
control
antimicrobi
drug
use
neglig
shortterm
effect
argu
howev
healthcar
regul
power
influenc
antimicrobi
drug
use
futur
underlin
hypothesi
give
exampl
differ
contin
selfmed
import
driver
antimicrobi
overus
lowand
middleincom
countri
therefor
sinc
chilean
ministri
health
strictli
enforc
exist
law
restrict
purchas
antimicrobi
agent
without
medic
prescript
regulatori
measur
sustain
impact
antimicrobi
use
outpati
set
sale
oral
use
antimicrobi
agent
decreas
us
million
us
million
figur
inadequ
prolong
periop
antimicrobi
prophylaxi
increas
resist
antimicrobi
drug
royal
decre
belgium
limit
reimburs
antimicrobi
drug
prophylaxi
specif
agent
period
surgeri
moreov
fix
fee
antimicrobi
cost
attribut
type
intervent
shown
tabl
regulatori
restrict
sustain
effect
use
antimicrobi
prophylaxi
belgium
europ
north
america
separ
antimicrobi
prescrib
dispens
wellestablish
system
contrast
mani
asian
countri
healthcar
provid
earn
signific
proport
incom
dispens
drug
especi
broadspectrum
antimicrobi
agent
consequ
physician
tradit
compens
rel
low
medic
servic
revenu
prescrib
high
volum
antimicrobi
agent
strong
opposit
physician
pharmaceut
industri
new
korean
govern
polici
prohibit
physician
dispens
drug
pharmacist
prescrib
drug
new
polici
decreas
overal
prescrib
antimicrobi
agent
select
reduc
inappropri
prescrib
patient
viral
infect
uncertainti
evolv
around
microand
macrolevel
determin
influenc
antimicrobi
resist
make
longterm
predict
challeng
although
simul
studi
may
provid
guidanc
shortterm
trend
longterm
predict
futur
antimicrobi
resist
fraught
difficulti
shown
look
back
histori
antimicrobi
drug
era
began
scientist
impress
mileston
antimicrobi
agent
discoveri
issu
predict
futur
antimicrobi
resist
seem
overli
optimist
today
instanc
famou
french
microbiologist
anticip
pneumococci
gonococci
meningococci
would
chang
antimicrobi
suscept
profil
futur
pour
une
qui
au
sera
toujour
aussi
sensibl
cest
le
ca
de
germ
sensibl
la
gonocoqu
pneumocoqu
yet
exactli
year
later
rapidli
progress
toward
postantimicrobi
era
doctor
may
becom
helpless
even
common
infect
last
part
articl
contempl
possibl
statu
antimicrobi
resist
although
direct
major
trend
seem
rel
easi
factor
drive
uncertainti
present
tremend
forecast
challeng
therefor
develop
altern
scenario
futur
dissemin
control
antimicrobi
resist
extrapol
key
determin
discuss
earlier
inform
reader
may
apolog
lack
imagin
observ
chang
prescrib
habit
attitud
toward
outpati
antimicrobi
use
especi
respiratori
infect
polici
behavior
chang
intervent
contribut
massiv
chang
social
norm
around
antimicrobi
drug
use
similar
happen
tobacco
control
intens
educ
campaign
aim
optim
antimicrobi
drug
use
combin
immun
program
infant
children
lead
reduc
spread
clinic
impact
antimicrobialresist
pneumococci
tool
inform
technolog
progress
microbiolog
reduc
diagnost
uncertainti
improv
antimicrobi
dose
select
treatment
durat
use
antimicrobi
agent
therefor
continu
decreas
outpati
set
also
inpati
set
new
therapi
develop
base
probiot
principl
technolog
advanc
enhanc
identif
character
vast
microbi
divers
colon
human
bodi
commens
pathogen
may
lead
new
probiot
strategi
prevent
infect
reduc
antimicrobi
select
pressur
data
share
increas
intern
cooper
lead
consist
control
measur
across
differ
contin
asian
countri
user
larg
amount
antimicrobi
agent
import
driver
resist
recent
chang
paradigm
introduc
modern
infect
control
concept
public
health
polici
decreas
overus
antimicrobi
agent
antimicrobi
resist
among
import
pathogen
slowli
revers
trend
antimicrobi
resist
follow
sshape
curv
quick
ascent
plateau
sometim
slow
declin
antimicrobi
resist
high
preval
countri
slowli
reduc
especi
sever
gramposit
microorgan
antimicrobi
resist
major
impact
life
expect
industri
world
death
panresist
infect
without
treatment
option
remain
rare
complic
highincom
countri
sinc
new
antimicrobi
agent
better
use
current
avail
antimicrobi
drug
becom
standard
polici
new
resist
mechan
emerg
dissemin
multiresist
group
streptococci
render
penicillin
macrolid
useless
treatment
pharyng
salmonella
spp
infect
longer
treat
advanc
cephalosporin
fluorquinolon
carbapenem
observ
rais
resist
rate
pathogen
multiresist
acinetobact
spp
enterococci
staphylococci
caus
substanti
ill
increas
treatment
cost
part
world
instal
stringent
control
measur
healthcareassoci
infect
due
vancomycinresist
enterococci
becom
endem
mani
countri
antibacterialresist
aureu
becom
massiv
public
health
problem
scope
staphylococc
antimicrobi
resist
extend
new
antimicrobi
agent
also
set
although
hospit
sole
provinc
methicillinresist
aureu
mrsa
commun
outbreak
mrsa
occur
person
lack
tradit
risk
factor
carriag
mrsa
preval
mrsa
us
commun
reach
within
next
decad
rate
time
high
hospit
technolog
develop
fulfil
promis
new
antimicrobi
class
treatment
strategi
develop
gramneg
bacteria
vaccin
wide
effect
serotyp
replac
pneumococci
allow
organ
escap
control
fluoroquinolon
longer
effect
wide
array
infect
replac
new
class
oral
avail
antimicrobi
agent
new
antimicrobi
drug
novel
mechan
action
eg
bacteriophag
fail
larg
phase
iii
trial
anthrax
pandem
influenza
threat
led
mass
prophylaxi
disastr
consequ
term
resist
sever
disast
pandem
increas
use
antimicrobi
drug
global
scale
lead
emerg
dissemin
resist
continu
flood
consensu
confer
statement
posit
paper
surveil
network
report
issu
problem
antimicrobi
resist
without
measur
sustain
effect
contain
healthcar
polici
introduc
stringent
control
measur
lack
precis
estim
public
health
impact
antimicrobi
resist
prioriti
press
infecti
diseas
problem
hiv
tuberculosi
malaria
high
level
uncertainti
complex
regard
antimicrobi
resist
mandat
build
capabl
prepar
specif
futur
follow
pessimist
viewpoint
antimicrobi
therapi
use
lose
also
across
rang
altern
scenario
may
less
pessimist
whether
current
epidem
antimicrobi
resist
sustain
succumb
current
effort
limit
spread
decid
interact
factor
relat
microorgan
host
use
pattern
antimicrobi
drug
impact
infect
control
measur
technolog
develop
hope
ad
infect
control
prudent
use
antimicrobi
agent
new
drug
develop
avert
realiz
pessimist
predict
futur
antimicrobi
resist
dr
samor
professor
intern
medicin
univers
utah
chief
divis
clinic
epidemiolog
also
director
salt
lake
informat
decis
enhanc
surveil
center
research
interest
includ
antimicrobi
resist
hospit
commun
computerdecis
support
prescrib
antimicrobi
agent
surveil
error
advers
event
